ANIP
NASDAQ · Pharmaceuticals
Ani Pharmaceuticals Inc
$78.25
-4.38 (-5.30%)
Financial Highlights (FY 2026)
Revenue
901.36M
Net Income
79.93M
Gross Margin
61.4%
Profit Margin
8.9%
Rev Growth
+40.8%
D/E Ratio
1.14
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 61.4% | 61.4% | 50.7% | 50.7% |
| Operating Margin | 12.6% | 11.3% | 18.0% | 18.0% |
| Profit Margin | 8.9% | 8.4% | 13.1% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 901.36M | 640.13M | 587.23M | 677.58M |
| Gross Profit | 553.07M | 392.78M | 297.61M | 343.40M |
| Operating Income | 113.39M | 72.47M | 105.58M | 122.17M |
| Net Income | 79.93M | 51.09M | 76.98M | 94.84M |
| Gross Margin | 61.4% | 61.4% | 50.7% | 50.7% |
| Operating Margin | 12.6% | 11.3% | 18.0% | 18.0% |
| Profit Margin | 8.9% | 8.4% | 13.1% | 14.0% |
| Rev Growth | +40.8% | +40.8% | +23.0% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 457.43M | 457.43M | 377.30M | 386.46M |
| Total Equity | 400.76M | 400.76M | 736.99M | 759.49M |
| D/E Ratio | 1.14 | 1.14 | 0.51 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 206.64M | 139.41M | 125.34M | 137.44M |
| Free Cash Flow | — | — | 59.62M | 74.72M |